CRISPR Therapeutics
CRSP
446 hedge funds and large institutions have $3.27B invested in CRISPR Therapeutics in 2021 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 162 increasing their positions, 129 reducing their positions, and 96 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
26% more repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 129
10% more call options, than puts
Call options by funds: $232M | Put options by funds: $210M
3.22% more ownership
Funds ownership: 53.07% → 56.29% (+3.2%)
6% less funds holding
Funds holding: 474 → 446 (-28)
22% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 96
28% less capital invested
Capital invested by funds: $4.53B → $3.27B (-$1.26B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$131M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$94.1M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$90M |
| 4 |
Renaissance Technologies
New York
|
+$50.6M |
| 5 |
AC
Armistice Capital
New York
|
+$44.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$85.9M |
| 2 |
O
OrbiMed
New York
|
-$68.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$51.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$32.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$28.6M |
CRSP Hedge Fund Activity: Q4 2021 in Review
446 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2021, worth a combined $3.27B — down 28% from $4.53B a quarter earlier.
Sellers outnumbered buyers: 96 funds closed out of CRSP and 75 opened new positions — a net loss of 21 holders — while 129 trimmed existing stakes and 162 added.
The largest buyer was ARK Investment Management, adding an estimated $131M. The largest seller was Macquarie Group, cutting an estimated $85.9M.
- 446 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2021, down from 474 in Q3 2021.
- Funds reported $3.27B of CRISPR Therapeutics stock for Q4 2021, down 28% quarter-over-quarter.
- 75 funds opened new CRISPR Therapeutics positions in Q4 2021 and 96 closed out, a net change of -21 holders.
- The largest CRISPR Therapeutics buyer in Q4 2021 was ARK Investment Management, an estimated $131M added.
- The largest CRISPR Therapeutics seller in Q4 2021 was Macquarie Group, an estimated $85.9M sold.
Based on aggregated 13F filings for Q4 2021.